Home Search
"life science" - search results
If you're not happy with the results, please do another search
Institutional investor profile, Claus Stenbaek, executive director and partner, Danske Private Equity
Danske Private Equity is part of the Danske Bank Group and runs two direct funds, Danske Venture Partners and Danske Life Sciences. It also runs two fund of funds vehicles, the E500m Danske Private Equity Partners I and Danske Private Equity Partners II, which is currently raising E600m, with a first closing expected before the end of this year. Claus Stenbaek has been with Danske since 2000 and was previously founder of London-based Richmond Capital.
Why is there so much confidence in biotech?
Biotech has traditionally been considered a risky option for investors. But this is no longer the case, argues Dr Hellmut Kirchner of Venture Capital Management. He explains why, in many respects, biotech is now a safer bet for investors than other, more fashionable industries.
Nestle to launch CHF 200m corporate venturing fund
Swiss food giant Nestle has announced plans to launch a CHF 200 million corporate venturing fund to invest in strategically attractive small businesses. It will be managed by an independent team and will focus on the food and life sciences sectors.
Developments in German venture capital
The German venture capital market has grown rapidly in the last four years but how does it compare to the more mature UK market? This executive summary taken from the CMBOR quarterly review gives an outline of some of Germany's main characteristics.
Despite tough market, five venture-backed companies squeak out successful IPOs in Q3
Venture-backed offerings were few and far between in the US domestic IPO market, according to these latest figures from NVCA and Venture Economics. Just five venture-backed US based companies managed to execute public offerings over the past three months, raising a total of $279.9m.
Investor profile: Ray Maxwell, managing director, INVESCO Asset Management
Maxwell on why fee structures are biased, on the argument against large buy-out funds and on the re-emergence of internet investments.
People: September 2001
Cybulski joins Almeida, Royal Bank of Scotland expands in Germany and Colloton becomes COO at Bessemer...
Funds: September 2001
New biotech fund for Eli Lilly, debut fund of funds for Schroders, green VC fund for Triodos Bank, final closing for Parthenon, JP Morgan cuts fund target…
Belgium’s Gimv unveils 16 per cent profit growth
Gimv, the Belgian listed investment company, has reported a 16 per cent increase in its profits for the first half of the year to E76m, from E65.2m in the same period last year.
Schroder’s life sciences team hires three new partners
Schroder Ventures Life Sciences has appointed three new venture partners for its London and Boston offices.